Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.
Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.
Lemieux
B
B
Haematology Department, Centre Hospitalier Lyon Sud, Hospices civils de Lyon - Université Claude Bernard, Pierre-Benite, France.
Tartas
S
S
Traulle
C
C
Espinouse
D
D
Thieblemont
C
C
Bouafia
F
F
Alhusein
Q
Q
Antal
D
D
Salles
G
G
Coiffier
B
B
D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000737:chemistry*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology*; D009504:Neutrophils / Q000378:metabolism; D000069283:Rituximab; D033581:Stem Cell Transplantation; D013997:Time Factors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D000069283:Rituximab